A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

To join this study, you would need to be an adult, aged 18 or older.

Specifically, you must have a confirmed diagnosis of Gastrointestinal Stromal Tumours (GIST) that has either spread to other parts of your body or cannot be completely removed by surgery. It's also important that your GIST has continued to grow or caused problems even after you've been treated with the drug imatinib. The doctors will also need to review some tissue from your cancer, either from an old biopsy or by taking a new small sample.

There are also some reasons why you might not be able to join. For example, if you have cancer that has spread to your brain and isn't being treated, or if you've had a bad allergic reaction to similar drugs in the past. Also, if you have another type of cancer that has recently spread or needed active treatment, you might not be able to participate, unless it's a very common skin cancer or a very early-stage cancer that has been successfully removed.

Taking part in this study would involve regular visits to the clinic for check-ups and to receive your study medication, which would be either IDRX-42 or sunitinib. You wouldn’t get to choose which one you receive. During these visits, the medical team will monitor your health, check how you're responding to the treatment, and look out for any side effects. This will involve regular blood tests, scans (like CT scans) to see how your GIST is responding, and assessments of your general well-being.

The study would last for a period of time decided by the doctors, which will include the treatment phase and a follow-up period to continue monitoring your health and the effects of the medication. The research team will explain all the details, including the schedule of visits and procedures, before you decide to join.